Eupraxia Pharmaceuticals
EPRX | NASDAQ
$7.34
-$0.81 (-9.94%)
At close: Nov 16, 2026, 4:00 PM ET
$7.34
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Eupraxia Pharmaceuticals Company Profile
Company profile explainedCompany Profile
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
Key Executives
| Name | Position |
|---|---|
| James A. Helliwell FRCPC | Chief Executive Officer & Director |
| Alexander John Rothwell | Chief Financial Officer |
| Alex Therien | Executive VP of R&D |
| Jeffrey Millard | Executive Vice President of Technical Operations |
| Jeymi Tambiah | Chief Medical Officer |
| Paul Anthony Brennan | Chief Corporate Development Officer |
| Wajida Leclerc CHRP | Executive Vice President Corporate Services & People |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 22, 2026 | 6-K | Filing |
| Oct 15, 2026 | 6-K | Filing |
| Oct 09, 2026 | 6-K | Filing |
| Sep 30, 2026 | 6-K | Filing |
| Sep 08, 2026 | 6-K | Filing |
| Sep 02, 2026 | SUPPL | Filing |
| Aug 24, 2026 | EFFECT | Filing |
| Aug 19, 2026 | F-10/A | [Amend] Filing |
| Aug 13, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 13, 2026 | 6-K | Filing |
Eupraxia Pharmaceuticals
| Country | Canada |
| IPO Date | Apr 5, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 49 |
| CEO | James A. Helliwell |
Contact Details
2067 Cadboro Bay Road Victoria,
BC V8R 5G4 Canada
Stock Details
| Ticker Symbol | EPRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001581178 |
| CUSIP Number | 29842P105 |
| ISIN Number | CA29842P1053 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove EPRX